Micregen  has an innovative pipeline to tackle some of the most devastating and life-changing health problems in neonates, infants and adults using allogeneic stem cell derived Secretomix.

Micregen’s pipeline of therapeutics aim to impact on a range of diseases and illness from neonates through to those that effect the elderly and infirm. Building on research spanning decades, Micregen is focused on translating this innovation from the laboratory to the clinic.​

Micregen aim to make a significant impact on global health by offering first in class treatment options across a wide range of multiple inflammatory and degenerative conditions.  

Indication
Product
Research & Development
Discovery
Optimisation
Discovery & Optimisation
Clinical Translation
Preclinical
Phase I
Phase II
Necrotising
Entrocolitis
MRG1061
Pulmonary
Hypoplasia
MRG1061
Disuse-associated
Muscle Atrophy
MRG1161
Products

Micregen have two allogeneic products in pre-clinical development:

  • MRG1061 is Micregen’s first product targeting neonatal conditions. It is a multipotent stem cell-derived, cell-free injectable Secretomix, designed to aid tissue regeneration
  • MRG1161 is Micregen’s second product. MRG1161 is a pluripotent stem cell-derived, cell-free injectable Secretomix, designed to alleviate problems associated with ageing
CONTACT US